Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.
Scholar Rock Chief Scientific Officer Conducts Multiple Sales Throughout January 2026 The Chief Scientific Officer of Scholar Rock Holding Corp has made multiple filings regarding disposals in January 2026, but this should not alarm investors.
Nasdaq Bears Dig In: Short Interest Hits Record 18.38 Billion Shares Amid Valuation Anxiety As the final trading days of 2025 approach, the Nasdaq has reached a staggering milestone that has both bulls and bears on edge. According to the latest settlement data released on December 15, 2025, total short interest across the Nasdaq exchange has surged to a record 18.38 billion shares.
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.
Why Is Scholar Rock Holding Stock Climbing Today? Scholar Rock shares jump after the company strengthened its cash runway into 2027 and advanced launch preparations for its lead drug candidate, apitegromab.
Why Did Scholar Rock Soar 26% Today? The company is planning to reapply for approval of a muscle atrophy therapy in the coming year.
Let's uncover which stocks are experiencing notable gaps during today's session. There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.
Scholar Rock Holding Corp (NASDAQ:SRRK) Posts Wider-Than-Expected Q3 2025 Loss Amid Key Launch Preparations Scholar Rock invests heavily in its lead drug apitegromab, targeting a 2026 launch for spinal muscular atrophy despite a wider Q3 2025 loss.
Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks Lucid, Avis, Hims & Hers Health and Upstart are some of the most heavily shorted stocks right now. Here's a look at the top ten.
Why Scholar Rock Stock Got Socked on Monday The biotech suffered a regulatory setback last month, and this new development might be another blow to its prospects.
Why Is Scholar Rock Stock Trading Lower On Monday? Scholar Rock stock falls as FDA issues Form 483 to Catalent; company to meet FDA, while apitegromab shows lean mass preservation in trial.
Why Are Regeneron And Scholar Rock Shares Falling On Monday? Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk.
